Tyrian Diagnostics (TDX)

Shares / Stock Code

TDX

Stock Exchange / Sharemarket

ax

Tyrian Diagnostics (TDX) is an Australian-based company which develops and commercialises rapid point-of-need diagnostics for clinical and non-clinical applications. Tyrian’s objective is to generate recurring revenues from a portfolio of rapid point-of-need diagnostic products. The Company’s strategy is to deliver near term revenues through commercialisation of clinical and agricultural products on its patented DiagnostIQTM platform. Longer term, Tyrian intends to develop higher value proprietary products for respiratory infectious disease. Investors can trade Tyrian Diagnostics shares on the Australian Stock Exchange (ASX).

Tyrian has developed an innovative and proprietary diagnostic test platform, DiagnostIQ. The DiagnostIQ platform comprises a patented disposable test device which can be used alone or together with the DiagnostIQ Reader. DiagnostIQ can be used for the development of diagnostic tests where accurate and time critical results are required to determine action to be taken at the point-of-care (human health clinical tests) or in-field (agricultural and environmental tests). TDX was listed on the Australian stock market in 30 September, 2004.

Tyrian also has expertise in discovering and developing biomarkers of disease as targets for diagnostic tests, particularly in respiratory and infectious disease. The Company’s longer term plan is to exploit its intellectual property and expertise in this area through developing and partnering higher value proprietary clinical diagnostics. Tyrian Diagnostics’ headquarters is located in North Ryde, Sydney, Australia.

Tyrian Diagnostics has also expertise in protein biomarker discovery and validation of these biomarkers as diagnostic reagents. We have developed proprietary methods for separating proteins of potential interest from complex clinical samples; and for enriching the concentration of low abundant or rare proteins for detection in diagnostic systems. Promising biomarkers are validated through Tyrian Diagnostics’ technology pipeline for potential application as diagnostic and prognostic tests, for monitoring disease progression and the effectiveness of drug treatments, or as surrogate markers in clinical trials.

They commercialise their products through partnerships with well established marketing and distribution companies. It is their aim to work closely with their partners throughout the commercialisation process in order to maximize the profitability of company's products.